Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on May 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Press release furnished as Exhibit 99.1 under Item 1.01.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Press release furnished as Exhibit 99.1 under Item 1.01
- Material agreement details require review of Exhibit 99.1 for deal terms and obligations
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer regarding Exchange Act and Securities Act liability
- No substantive investor information or operating update in the provided excerpt
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.